Clovis Corporate Presentation

September 2021

CLOVIS ONCOLOGY

Forward-looking Statements

To the extent that statements contained in this presentation are not descriptions of historical facts regarding Clovis Oncology, they are forward-looking statements reflecting the current beliefs and expectations of management. Examples of forward-looking statements contained in this presentation include, among others, statements regarding our expectations for commercial launches, availability of study data and submission of regulatory filings. Such forward-looking statements involve substantial risks and uncertainties that could cause our future results, performance or achievements to differ significantly from that expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, whether future study results will support continued development, the timing of availability of data from our clinical trials, the uncertainties inherent in actions or decisions by the FDA, the EMA or other regulatory authorities regarding whether to accept or approve drug applications that may be filed, including delays or denials of regulatory approvals, clearances or authorizations for applications, as well as their decisions regarding drug labeling, reimbursement and pricing. These forward-looking statements speak only as of the date hereof. Clovis Oncology does not undertake to update or revise any forward-looking statements. A further description of risks and uncertainties can be found in Clovis Oncology's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its reports on Form 10-Q and Form 8-K.

CLOVIS ONCOLOGY

Investment Highlights

Oncology Focused	A biopharmaceutical company focused on the development and commercialization of innovative anti-cancer therapies
Rubraca: Three Phase 3 Readouts over Next ~6-18 months	Oral, small molecule PARP inhibitor approved for multiple indications in the US and Europe Three Phase 3 readouts anticipated which offer potential for label expansion: • ATHENA trial of Rubraca® (rucaparib) as 1LM OC monotherapy anticipated 1Q22 • TRITON3 trial in second-line mCRPC anticipated 2Q22 • ATHENA trial of Rubraca as 1LM OC combination with Opdivo® (nivolumab) anticipated 2H22
Commitment to Targeted Radionuclide Development	Targeted radionuclide therapeutics represent promising new field of oncology development • Initial target is FAP which is highly expressed in many epithelial cancers, including more than 90% of breast, lung, colorectal and pancreatic carcinomas • Phase 1/2 LuMIERE study of FAP-2286 open for enrollment; initial data expected in 2022 • Ongoing discovery program to identify additional targeted radionuclide development targets
Financial Resources	Commitment to achieve long-term financial stability • Increase Rubraca revenues with label expansions • Reduced R&D spend on Rubraca, new R&D spend dedicated to targeted radionuclide therapy program • Ongoing cost containment efforts and prudent use of capital

1LM = first line maintenance, OC = ovarian cancer, mCRPC = metastatic castration-resistant prostate cancer, FAP = fibroblast activation protein, I/O = immuno-oncology

CLOVIS ONCOLOGY

Rubraca: Multiple Approved Indications

Rubraca® (rucaparib) 300 mg tablets



Source: Rubraca [prescribing information]. Boulder, CO; Clovis Oncology.

CLOVIS ONCOLOGY

Drive Rubraca Revenue Growth through Label Expansion

Three topline Phase 3 data readouts over the next ~6-18 months

Q1 2022	**Front-line Ovarian Cancer Maintenance – ATHENA Monotherapy**
Q2 2022*	**Second-line mCRPC – TRITON3**
2H 2022*	**Front-line I/O Combo Ovarian Cancer Maintenance – ATHENA Combo**

Potential to address larger patient populations in earlier lines of therapy in US and Europe

*Expected timing of data readout is dependent on the timing of data maturity driven by PFS events
ATHENA clinicaltrials.gov identifier NCT03522246, TRITON3 clinicaltrials.gov identifier NCT02975934
mCRPC = metastatic castration-resistant prostate cancer, I/O = immuno-oncology
Sources: ASCO 2020, Moses et al., Bleachler et al., Journal of Ovarian Research 2020, Bono et al., European Association of Urology 2017, Value In Health, A619 2014. Wallace et al., PharmacoEconomics, 2020 and data on file.

CLOVIS ONCOLOGY

Ovarian Cancer Remains a Difficult Diagnosis; Rubraca Offers Clear Therapeutic Option for Women with Recurrent Disease

- Estimated 21,410 new cases and 13,770 deaths in the US in 2021
- Although most patients with advanced ovarian cancer respond to initial treatment, the majority will experience disease recurrence and require subsequent therapies
- Up to 60% of patients with ovarian cancer may be HR-deficient



HR = homologous recombination, PFS = progression free survival, INV = investigator assessed, IRR = independent radiologic review, ITT = intent to treat.

Sources: American Cancer Society Key Statistics https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html. Accessed August 2021.Bourberhan, et al j Clin Oncol 2019. Mukhopadhyay A, et al. Clin Cancer Res. 2010;16(8):2344-235. Rubraca [prescribing information]. Boulder, CO; Clovis Oncology. Data on file. Clovis Oncology; Boulder, CO.

CLOVIS ONCOLOGY

Rubraca in Europe for Recurrent Ovarian Cancer Maintenance Treatment Indication

- In January 2019, the European Commission approved the use of Rubraca for its second indication*
  - With the maintenance treatment indication, Rubraca is available to eligible patients regardless of their BRCA mutation status
- Rubraca commercially available in Germany, United Kingdom, Italy, France, Spain, Netherlands and Switzerland



*On 1st January 2021 following BREXIT the EU centralized marketing authorization (MA) was automatically converted to a Great Britain MA for rucaparib. Great Britain covers England, Scotland and Wales. Northern Ireland under the Northern Ireland protocol is still covered by the EU centralized MA.
Source: Rucaparib Summary of Product Characteristics. May 2019. Clovis Oncology, Inc.

mCRPC Remains a Difficult Diagnosis: Rubraca Demonstrated Efficacy and Durability in Men with a BRCA1/2 Mutation

- Approximately 43,000 men in the US were expected to be diagnosed with mCRPC in 2020
- Castrate-resistant prostate cancer has a high likelihood of developing metastases; mCRPC is an incurable disease, usually associated with poor prognosis
- The five-year survival rate for mCRPC is approximately 30%
- Approximately ~12% of mCRPC patients have a deleterious mutation in *BRCA1* or *BRCA2*

Rubraca TRITON2 Clinical Results

- 44% confirmed ORR (N=62; 95% CI 31, 57) by blinded-IRR
- Some responses remained ongoing at two years and ranged from 1.7-24+ months*
- 55% confirmed PSA response rate (N=115; 95% CI 45, 64)
- Safety data for men with mCRPC were consistent with prior safety reports for patients with ovarian cancer and other solid tumors

*Median DOR by blinded-IRR was not evaluable at data cut-off (N=62; 95% CI 6.4 months, NE)
mCRPC = metastatic castration resistant prostate cancer, ORR = overall response rate, IRR = independent radiologic review, PSA = prostate-specific antigen
Sources: Scher HI et al (2015) Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model. PLoS ONE 10(10): e0139440. doi:10.1371/journal.pone.0139440; Robinson et al. *Cell.* 2015; 161:1215-1228; Abida et al. *JCO Precis Oncol.* 2017;1:1-16; Rubraca [prescribing information]. Boulder, CO; Clovis Oncology. Anscher et al., *The Oncologist* 2020; 9999. Data on file. Boulder, CO; Clovis Oncology.

Targeted Radionuclide Therapy (TRT): Emerging New Therapeutic Class of Drugs to Treat Patients with Cancer

THERANOSTICS

IMAGING:
Seeing What We Treat

Use of a radionuclide suitable for imaging allows the clinician to see where the therapeutic agent will be delivered



THERAPEUTIC:
Treating What We See

TRTs have the potential to deliver therapeutic doses of radiation specifically to the tumor

- FAP-2286 belongs to a class of “theranostics” which are compounds which may potentially be used as therapeutic or imaging agents
- Clovis is developing FAP-2286, a peptide-targeted radionuclide therapy targeting fibroblast activation protein (FAP), as well as a discovery program for three additional targets with its partner 3B Pharmaceuticals

CLOVIS ONCOLOGY

Fibroblast Activation Protein is a Pan-Tumor Target Highly Expressed in Cancer-Associated Fibroblasts

- Fibroblast activation protein (FAP) is highly expressed in cancer-associated fibroblasts (CAFs) which are found in the majority of cancer types, potentially making it a suitable target across a wide array of tumors
  - FAP has limited expression on normal fibroblasts reducing the potential for FAP-targeted agents having effects in normal tissue



Representative images of FAP-expressing tumors by IHC



Sources: ESMO 2020, Zboralski et al. Rettig et al, Clin Cancer Research 1993. Clovis internal data: Tumor microarrays (TMAs) were stained with FAP antibody SP325 (HistoGenX)

FAP-2286 is a Potent and Selective FAP-Targeting Agent with a Promising Preclinical Profile for PTRT

- FAP-2286 consists of two functional elements:
  - A peptide that binds to FAP
  - A site that can be used to attach radioactive isotopes for imaging (e.g. Gallium-68; ^{68}Ga) or therapeutic (Lutetium-177; ^{177}Lu) use
- Nonclinical studies have demonstrated that FAP-2286 potently and selectively binds to FAP

FAP-2286*



^{177}Lu-FAP-2286 SPECT/CT imaging in FAP^{+ve} tumor model**



- In vivo imaging in mice after IV showed ^{177}Lu-FAP-2286 uptake in FAP-positive HEK-FAP xenografts at all time points evaluated

PTRT = Peptide-targeted radionuclide therapy
*FAP binding peptide image added for illustrative purposes only. Does not represent actual sequence of FAP lead candidate; **%ID/g, percent injected dose of test article per gram of tissue.
Source: ESMO 2020, Zboralski et al.

Anti-tumor Efficacy of ^{177}Lu-FAP-2286 Observed in FAP-Expressing Tumor Models

- A single, IV dose of ^{177}Lu-FAP-2286 resulted in statistically significant tumor growth inhibition in two different xenograft models:
  - HEK293 cells stably transfected with human FAP (HEK-FAP)
  - Sarcoma Sarc4809 patient-derived xenograft model with endogenous FAP expression



Source: ESMO 2020, Zboralski et al. When tumors reached a mean tumor volume of 160±44 mm^3 (HEK-FAP) and 187±124 mm^3 (Sarc4809), mice (n=10/group) were treated with a single dose of the indicated agents. Statistically significant tumor regression was observed at both dose levels of ^{177}Lu-FAP-2286 evaluated in the HEK-FAP (P<0.05) and Sarc4809 (P<0.0001) models.

Broad FAP-2286 Clinical Development Program Planned

- LuMIERE Phase 1 study open for enrollment to determine safety and tolerability of ^{177}Lu-FAP-2286 and the recommended Phase 2 dose of ^{177}Lu-FAP-2286 to be used as a FAP-targeted therapeutic agent
  - ^{68}Ga-FAP-2286 will be utilized as FAP-targeted imaging agent to identify tumors that contain FAP for treatment in Phase 1 study
- Anticipated 2022 milestones:
  - First presentation of initial LuMIERE Phase 1 data; initiation of LuMIERE Phase 2 cohorts expected in multiple tumor types
  - Launch combination study program
  - Potential IND filing of an FAP-targeted α-emitter PTRT
- Potential for accelerated approvals in multiple tumor types
- Investigator-initiated trial (IIT) ongoing at UCSF: Phase 1 single-arm imaging study with dosimetry and imaging cohorts using ^{68}Ga-FAP-2286 in patients with solid tumors

LuMIERE clinicaltrials.gov identifier NCT04939610
UCSF IIT clinicaltrials.gov identifier NCT04621435

CLOVIS ONCOLOGY

Phase 1 LuMIERE Advanced Solid Tumors Study Design

First PTRT targeting FAP to enter clinical development



Primary Objectives: To evaluate the safety and tolerability of ^{177}Lu-FAP-2286 and determine the recommended Phase 2 dose (RP2D)

Secondary Objectives: Evaluate radiation dosimetry, PK, and preliminary efficacy of ^{177}Lu-FAP-2286 in advanced solid tumors; assess safety and tumor uptake of the imaging agent, ^{68}Ga-FAP-2286, as compared to 2-deoxy-2-[18F]fluoro-D-glucose (FDG)

The trial is being conducted in the US

ECOG = Eastern Cooperative Oncology Group; RP2D = recommended phase 2 dose; GBq = gigabecquerel; mCI = millicurie; PK = pharmacokinetics

Clinicatrials.gov https://clinicaltrials.gov/ct2/show/NCT04939610. Accessed August 25, 2021

Commitment to Building Targeted Radionuclide Therapeutic Pipeline



- Ongoing discovery collaboration with 3B Pharmaceuticals provides robust targeted radionuclide therapy pipeline
- Potential IND for second radiotherapeutic candidate in 2H 2022

CLOVIS ONCOLOGY

Lucitanib: Novel Oral Tyrosine Kinase Inhibitor

- Investigational angiogenesis inhibitor which inhibits vascular endothelial growth factor receptors 1-3 (VEGFR1-3), platelet derived growth factor receptors (PDGFR) α/β and fibroblast growth factor receptors 1-3 (FGFR1-3)
- Initial LIO-1 Phase 1b data in advanced metastatic solid tumors presented at ESMO 2020
- Interim data from LIO-1 Phase 2 non-clear-cell ovarian cancer expansion cohort presented at ASCO 2021
  - While evidence of clinical activity was observed, efficacy data not supportive of further development in non-clear-cell ovarian cancer
- Enrollment continues in three other LIO-1 Phase 2 gynecologic cancer expansion cohorts
- Data from additional cohorts, expected to be presented at future medical meetings, will inform potential clinical and commercial decisions about the lucitanib program

Financial Overview

- Q2 2021 global net revenues of $36.8M
  - US product revenue $27.7M; ex-US product revenue $9.1M
- Cash and equivalents expected to fund operating plan for at least the next 12 months
  - Cash and cash equivalents of $230.2M and $48.1M available funding under the ATHENA financing at June 30, 2021
- Ongoing effects of COVID-19 disruption and timing of recovery are difficult to predict
- Commitment to achieve long-term financial stability

CLOVIS ONCOLOGY

Commitment to Achieve Long-term Financial Stability

- Drive Rubraca revenue growth in US and Europe
- Three Rubraca Phase 3 trial read-outs in next 6-18 months
- Increase Rubraca revenues with label expansion
- Reduced R&D spend on Rubraca, new R&D spend dedicated to targeted radionuclide therapy program
- Lower total SG&A spending
- Ongoing cost containment efforts and prudent use of capital

Investment Highlights

Oncology Focused	A biopharmaceutical company focused on the development and commercialization of innovative anti-cancer therapies
Rubraca: Three Phase 3 Readouts over Next ~6-18 months	Oral, small molecule PARP inhibitor approved for multiple indications in the US and Europe Three Phase 3 readouts anticipated which offer potential for label expansion: • ATHENA trial of Rubraca® (rucaparib) as 1LM OC monotherapy anticipated 1Q22 • TRITON3 trial in second-line mCRPC anticipated 2Q22 • ATHENA trial of Rubraca as 1LM OC combination with Opdivo® (nivolumab) anticipated 2H22
Commitment to Targeted Radionuclide Development	Targeted radionuclide therapeutics represent promising new field of oncology development • Initial target is FAP which is highly expressed in many epithelial cancers, including more than 90% of breast, lung, colorectal and pancreatic carcinomas • Phase 1/2 LuMIERE study of FAP-2286 open for enrollment; initial data expected in 2022 • Ongoing discovery program to identify additional targeted radionuclide development targets
Financial Resources	Commitment to achieve long-term financial stability • Increase Rubraca revenues with label expansions • Reduced R&D spend on Rubraca, new R&D spend dedicated to targeted radionuclide therapy program • Ongoing cost containment efforts and prudent use of capital

1LM = first line maintenance, OC = ovarian cancer, mCRPC = metastatic castration-resistant prostate cancer, FAP = fibroblast activation protein, I/O = immuno-oncology

CLOVIS ONCOLOGY